#London #United Kingdom #Alzheimer's Disease #Cumulus Neuroscience #NeuLogiq Platform

Cumulus Neuroscience at AAIC 2026: A Groundbreaking Digital Task for Alzheimer's Trials

Cumulus Neuroscience made headlines at the Alzheimer's Association International Conference (AAIC) 2026 by unveiling innovative findings using their NeuLogiq® platform. The company presented data demonstrating that their two-minute digital cognitive task, known as Symbol Swap, not only matches but often surpasses traditional clinical assessment benchmarks in identifying early indicators of Alzheimer’s disease. The study's results were encapsulated in a poster presentation titled, _A Brief Digital Symbol-Coding Task Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment._

Key Findings from the Studies

Across three separate studies, researchers found that the Symbol Swap task provided significant cognitive differentiation between control groups, those with Mild Cognitive Impairment (MCI), and Alzheimer's patients. Notably, the task was capable of detecting blood biomarker-defined Alzheimer's pathologies, delivering results with accuracy that met or exceeded well-established cognitive screeners like the ADAS-Cog, MoCA, and MMSE. This capability is especially crucial for pinpointing individuals who are asymptomatic yet possess underlying conditions that may contribute to Alzheimer's.

Dr. Brian Murphy, co-founder and Chief Science Officer of Cumulus, remarked on the implications of this technology. _“It is striking that a two-minute, patient-friendly task can match or beat assessments that take a trained clinician 10 to 45 minutes to administer,”_ he stated. He emphasized that the implications of this data point towards a significant advancement in trial efficiency—particularly vital for a condition as complex and time-sensitive as Alzheimer’s disease.

The Symbol Swap Task: Efficiency and Patient Engagement

Symbol Swap is a digital, tablet-based task that takes only two minutes to complete, reducing the burden on both participants and site staff in clinical trials. The remote adaptability of this tool is particularly appealing for large-scale multi-site studies, as it allows for both in-clinic and at-home assessments. This innovation not only streamlines the recruitment process for Alzheimer's trials but also aims to significantly reduce screen-failure rates, ultimately expediting the journey towards new therapies.

Impact on Alzheimer's Trial Recruitment

The research suggests that the Symbol Swap task can act as an effective first-line tool to identify individuals who are likely to benefit from follow-up tests involving plasma biomarkers such as pTau-217. Chief Commercial Officer for the Global Alzheimer's Platform, Lammert Albers, highlighted this potential, stating that findings may allow for the more effective selection of participants for subsequent blood-based biomarker testing. This method could shorten enrollment timelines and cut costs associated with traditional screening methods.

In addition to Symbol Swap, another presentation at the conference discussed the broader implications of the NeuLogiq platform, detailing how digital assessments—particularly those involving multiple dimensions like EEG assessments—could further enhance the efficacy and acceptance of clinical trials. Dr. James Rowe from the University of Cambridge elaborated on the findings, pointing out that these digital measures are not only well-tolerated by users but can also capture meaningful cognitive changes effectively.

Future Directions and Conclusion

Tina Sampath, CEO of Cumulus, underscored the critical need for innovations in participant recruitment within the Alzheimer's research field, characterizing it as a significant bottleneck. She insisted that user-friendly, low-cost digital tools like Symbol Swap could invigorate the process and effectively ease the burdens on both patients and research sites. The dual findings presented at AAIC 2026 collectively articulate a promising pathway toward transforming the clinical trial landscape for Alzheimer’s disease.

To learn more about Cumulus Neuroscience and their groundbreaking NeuLogiq platform, visit Cumulus Neuroscience.